Pioglitazone and bladder cancer risk: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pioglitazone and bladder cancer risk: a systematic review and meta-analysis

Published:2018-02-24 Issue:4 Volume:7 Page:1070-1080
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Tang Huilin¹²³,Shi Weilong³,Fu Shuangshuang⁴,Wang Tiansheng⁵,Zhai Suodi³,Song Yiqing¹²,Han Jiali¹²⁶^ORCID

Affiliation:

1. Department of Epidemiology; Richard M. Fairbanks School of Public Health; Indiana University; Indianapolis Indiana

2. Center for Pharmacoepidemiology; Richard M. Fairbanks School of Public Health; Indiana University; Indianapolis Indiana

3. Department of Pharmacy; Peking University Third Hospital; Beijing China

4. School of Public Health; The University of Texas Health Science Center at Houston; Houston Texas

5. Department of Epidemiology; Gillings School of Global Public Health; University of North Carolina at Chapel Hill; Chapel Hill North Carolina

6. Melvin and Bren Simon Cancer Center; Indiana University; Indianapolis Indiana

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1354/fullpdf

Reference60 articles.

1. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys;Kemnitz;Diabetes,1994

2. Pioglitazone after ischemic stroke or Transient Ischemic attack;Kernan;N. Engl. J. Med.,2016

3. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control - Results from the pioneer study;Pfützner;J. Am. Coll. Cardiol.,2005

4. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial;Dormandy;Lancet,2005

5. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study;Lewis;Diabetes Care,2011

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD);Life;2024-07-03

2. Amorfrutin B Compromises Hypoxia/Ischemia-induced Activation of Human Microglia in a PPARγ-dependent Manner: Effects on Inflammation, Proliferation Potential, and Mitochondrial Status;Journal of Neuroimmune Pharmacology;2024-07-01

3. New and emerging treatments for metabolic dysfunction-associated steatohepatitis;Cell Metabolism;2024-05

4. Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database;Diabetes, Obesity and Metabolism;2024-04

5. What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?;Drugs & Therapy Perspectives;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3